Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
// //

Medipharm Labs Corp TSX: LABS-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale

More stories below advertisement

Latest Press Releases

Another Near Billion-Dollar Cannabis Acquisition Signals More Hyper Valuations to Come
- PR Newswire - PRF - Fri Jul 9, 2:00PM CDT
PR Newswire - PRF - CMTX
Fri Jul 9, 2:00PM CDT
/PRNewswire/ --   -  As part of its recent cannabis M&A spree,  (NYSE: HEXO) (TSX: HEXO) spent nearly another billion dollars, acquiring  privately-owned licensed cannabis producer Redecan for . By adding Redecan, HEXO continues to grow its large portfolio of brands and production operations, as well as new cannabis 2.0 extraction-based products. Because of the size of the deal, the potential values of other Canadian cannabis brands, producers and extractors could be on the rise as additional M&A activity begins to swell in the leadup to potential legalization in the . Other Canadian companies that have been positioning themselves in this field include (OTC: PRXTF) (CSE: PULL) (XFRA: A2QJAJ),  (OTC: VLNCF) (TSX: VLNS),  (TSX: LABS) (OTC: MEDIF) and (NASDAQ: NEPT) (TSX: NEPT).
Number Of Cannabis Patents Granted In Europe & UK Growing At A Quick Pace
- PR Newswire - PRF - Thu Apr 29, 8:15AM CDT
PR Newswire - PRF - CMTX
Thu Apr 29, 8:15AM CDT
, /PRNewswire/ -- The worldwide explosion of the recreational and medical cannabis markets, and submarkets, appears that it will continue for years to come. New industries have been born, new mega-companies are growing and other new worldwide players will undoubtedly emerge. When new industries with almost unlimited revenue growth rates appear, the companies need an edge on their competition to survive the consolidations and mergers, to come out on top. Sometimes that edge is having and protecting their IP… with patents. An  from a UK and European Patent and Trade Mark Attorney firm discussed the view from the UK. It said: "Following high profile legalisation in territories around the world (for example , some states in the US and limited medicinal allowability in the UK), industry and financial institutions are recognizing the commercial potential of cannabis… And where there is commercial potential, there will be a demand to protect innovations made to capitalize on the market. A quick search on a global patent database indicates over 7000 granted patents which include the word cannabis, including over 1000 in and UK.  However, given that recreational cannabis is presently illegal in many places (for example, most places in and federally in the US), can you patent something which is illegal? Additionally, since cannabis is natural and has been known since ancient times, can you patent something which is so well known?"  Active companies in news today include:  (OTCQB: OILFF) (CSE: OILS), (NASDAQ: GWPH), (OTCQX: MEDIF) (TSX: LABS),  (NASDAQ: CGC) (TSX: WEED), (OTCQX: VLNCF) (TSX: VLNS).
Adjupharm Signs Supply Agreement with MediPharm Labs, Paving Way for IM Cannabis-Branded Extracts Launch in German Market
- ACCESSWIRE - Tue Apr 13, 6:50AM CDT
ACCESSWIRE - CMTX
Tue Apr 13, 6:50AM CDT
TORONTO, ON and BAD OLDESLOE, GERMANY and GLIL YAM, ISRAEL / ACCESSWIRE / April 13, 2021 / IM Cannabis Corp. ("IMC" or the "Company") (CSE:IMCC)(NASDAQ:IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational cannabis sector with operations in Canada, Israel and Germany, announced that its subsidiary, Adjupharm GmbH ("Adjupharm"), recently signed a supply agreement (the "Supply Agreement") with MediPharm Labs Australia Pty Ltd, a subsidiary of MediPharm Labs Corp. ("MediPharm Labs") (TSX:LABS), (OTCQX:MEDIF), (FSE:MLZ), a global leader in specialized, research-driven, pharmaceutical-quality cannabis extraction, distillation and derivative products. The initial term of the Supply Agreement is two years, with a two-year automatic extension period.
European Pharmaceutical Company STADA and MediPharm Labs Begin First Sales in Germany Under Exclusive Agreement
- GlobeNewswire - Thu Apr 1, 6:01AM CDT
GlobeNewswire - CMTX
Thu Apr 1, 6:01AM CDT
MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs") a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced STADA Arzneimittel AG (STADA), a leading European consumer health and generics company, and MediPharm Labs, under an exclusive, turnkey supply agreement, have commenced sales in Germany. As a result, patients in Germany are now able to access GMP-certified quality medical cannabis from STADA through local pharmacies under the brand - CannabiSTADA, distributed through STADAPHARM, a direct subsidiary of STADA.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies